Eqdx
Equilibrium Diagnostics offers a fast, low-cost urine test that detects tubular kidney dysfunction before conventional markers change. The company's AP Reader measures urinary ammonium and pH to generate a patented uAPI score, which predicts a more than 7-fold higher risk of kidney failure in matched CKD patients. This enables earlier intervention and better risk stratification to prevent disease progression.
- Artificial Intelligence
- Data & Analytics
- Biotechnology
- Hardware
- Healthcare Technology
- Medical Devices
- Software Only
Funding
Founders
Product
Problem
Chronic kidney disease affects more than 800 million people worldwide, yet standard tests measuring glomerular filtration (eGFR) and albuminuria (UACR) often detect dysfunction only after significant, irreversible damage has occurred. This oversight of tubular function leaves clinicians without a full view of kidney health, causing many patients to progress to end-stage kidney disease and dialysis that could have been delayed or prevented with earlier detection.
Solution
Equilibrium Diagnostics has developed the uAPI (urine Ammonium-pH Index), a patented diagnostic algorithm that uncovers tubular dysfunction from a single, routine urine sample. The company's AP Reader is an automated analyser that measures urinary ammonium and pH with gold-standard potentiometric precision28, then converts raw measurements into a clinically meaningful score. This score provides actionable risk stratification, allowing clinicians to identify high-risk patients earlier and guide referrals, treatment, and monitoring decisions. In matched CKD Stage 3–4 patients, a low uAPI predicts a more than 7-fold higher risk of a serious kidney event, and adding uAPI to standard clinical variables reclassifies over 60% of patients into a more accurate risk category. The test is designed to be synergistic with existing measures, addressing the critical detection gap that currently limits the effectiveness of new therapies that work best when started early.
Target Audience
Primary customers are clinical research laboratories and nephrology practices seeking earlier detection and better risk stratification for chronic kidney disease patients, as well as researchers studying acid-base balance, cystic fibrosis, and intestinal failure.
Features
- Direct measurement of urine pH, ammonium, titratable acidity, and bicarbonate from a standard urine sample
- Proprietary algorithm calculating the urine ammonium pH index (uAPI) as a single, clinically meaningful score
- AP Reader automated analyser with gold-standard potentiometric precision requiring no additional patient burden
- Demonstrated ability to reclassify >60% of CKD patients into more accurate risk categories when added to standard clinical variables
- Utility beyond CKD, including assessment of CFTR modulator efficacy in cystic fibrosis and quantification of metabolic acid burden in intestinal failure patients
- Quantification of renal net acid concentration and evaluation of net endogenous acid production for dietary and metabolic research